Literature DB >> 1319610

Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad.

D F Hunt1, H Michel, T A Dickinson, J Shabanowitz, A L Cox, K Sakaguchi, E Appella, H M Grey, A Sette.   

Abstract

Between 650 and 2000 different peptides are associated with the major histocompatibility complex class II molecule I-Ad. Sequences for nine of these were obtained by a combination of automated Edman degradation and tandem mass spectrometry. All of the peptides are derived from secretory or integral membrane proteins that are synthesized by the antigen-presenting cell itself. Peptides were 16 to 18 residues long, had ragged NH2-and COOH-termini, and contained a six-residue binding motif that was variably placed within the peptide chain. Binding data on truncated peptides suggest that the peptide binding groove on class II molecules can be open at both ends.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1319610     DOI: 10.1126/science.1319610

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  157 in total

1.  Introducing endogenous antigens into the major histocompatibility complex (MHC) class II presentation pathway. Both Ii mediated inhibition and enhancement of endogenous peptide/MHC class II presentation require the same Ii domains.

Authors:  K Frauwirth; N Shastri
Journal:  Immunology       Date:  2001-04       Impact factor: 7.397

Review 2.  Rous-Whipple Award Lecture. Chemical features of peptide selection by the class II histocompatibility molecules.

Authors:  E R Unanue
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

3.  Inhibition of allorecognition by a human class II MHC-derived peptide through the induction of apoptosis.

Authors:  B Murphy; C C Magee; S I Alexander; A M Waaga; H W Snoeck; J P Vella; C B Carpenter; M H Sayegh
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

4.  Hindering auxiliary anchors are potent modulators of peptide binding and selection by I-Ak class II molecules.

Authors:  R R Latek; S J Petzold; E R Unanue
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

5.  Specificity of peptide selection by antigen-presenting cells homozygous or heterozygous for expression of class II MHC molecules: The lack of competition.

Authors:  Anish Suri; James J Walters; Osami Kanagawa; Michael L Gross; Emil R Unanue
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-07       Impact factor: 11.205

6.  Alternate interactions define the binding of peptides to the MHC molecule IA(b).

Authors:  Xinqi Liu; Shaodong Dai; Frances Crawford; Rachel Fruge; Philippa Marrack; John Kappler
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-25       Impact factor: 11.205

Review 7.  Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.

Authors:  Michael C Jensen; Stanley R Riddell
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 8.  Dengue fever virus and Japanese encephalitis virus synthetic peptides, with motifs to fit HLA class I haplotypes prevalent in human populations in endemic regions, can be used for application to skin Langerhans cells to prime antiviral CD8+ cytotoxic T cells (CTLs)--a novel approach to the protection of humans.

Authors:  Y Becker
Journal:  Virus Genes       Date:  1994-09       Impact factor: 2.332

9.  Production and characterization of human proliferative T-cell clones specific for human papillomavirus type 1 E4 protein.

Authors:  J C Steele; T Stankovic; P H Gallimore
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

10.  Human HLA class I- and HLA class II-restricted cloned cytotoxic T lymphocytes identify a cluster of epitopes on the measles virus fusion protein.

Authors:  R S van Binnendijk; J P Versteeg-van Oosten; M C Poelen; H F Brugghe; P Hoogerhout; A D Osterhaus; F G Uytdehaag
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.